Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
| Title: | Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses |
|---|---|
| Authors: | Owonikoko, Taofeek K., Niu, Huifeng, Nackaerts, Kristiaan, Csoszi, Tibor, Ostoros, Gyula, Mark, Zsuzsanna, Baik, Christina, Joy, Anil Abraham, Chouaid, Christos, Jaime, Jesus Corral, Kolek, Vitezslav, Majem, Margarita, Roubec, Jaromir, Santos, Edgardo S., Chiang, Anne C., Speranza, Giovanna, Belani, Chandra P., Chiappori, Alberto, Patel, Manish R., Czebe, Krisztina, Byers, Lauren, Bahamon, Brittany, Li, Cong, Sheldon-Waniga, Emily, Kong, Eric F., Williams, Miguel, Badola, Sunita, Shin, Hyunjin, Bedford, Lisa, Ecsedy, Jeffrey A., Bryant, Matthew, Jones, Sian, Simmons, John, Leonard, E. Jane, Ullmann, Claudio Dansky, Spigel, David R. |
| Source: | In Journal of Thoracic Oncology February 2020 15(2):274-287 |
| Database: | ScienceDirect |
Be the first to leave a comment!